IM Cannabis Corp. (IMC) is an international cannabis company providing premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company has recently exited operations in Canada to focus on achieving sustainable and profitable growth in its highest-value markets. IMC leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With a commitment to responsible growth and compliance with strict regulatory environments, IMC aims to amplify its commercial and brand power to become a global high-quality cannabis player.
Key Strategic Focus
IMC's strategic focus centers on providing premium medical cannabis products in Israel and Germany. The company operates through its commercial relationship with Focus Medical Herbs Ltd. in Israel, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. IMC also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel, ensuring safe delivery and quality control throughout the value chain. In Germany, IMC operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients. The company utilizes its fully licensed EU-GMP packing facility and GDP logistics center to offer cannabis fulfillment services within the German market.
Financials and Funding
For the fiscal year ended December 31, 2023, IMC reported revenue of $48.8 million, a decrease from $53.3 million in 2022, primarily due to negative currency fluctuations and the impact of the Israel-Hamas war on operations. Gross profit increased to $9.8 million from $9.2 million in 2022. General and administrative expenses decreased by 49% to $11 million, and operating expenses decreased by 43% to $22.6 million. As of December 31, 2023, cash and cash equivalents were $1.8 million, with total assets of $48.8 million and total liabilities of $35.1 million.
In May 2025, IMC closed a non-brokered private placement of secured convertible debentures for aggregate proceeds of C$2,301,174.70. The debentures mature on May 26, 2026, and may be converted into common shares at a conversion price of C$2.61 per share. This funding aims to preserve cash to support accelerated growth in Germany.
Pipeline Development
IMC's pipeline development focuses on expanding its product offerings and market presence in Israel and Germany. In Germany, the company has experienced accelerated growth following the partial legalization of cannabis on April 1, 2024. IMC Germany delivered 182% growth in 2023, outperforming the market by 162%, and ranked #1 in sales per SKU. The company continues to bolster its supply chain with additional EU-GMP suppliers to support this growth.
Technological Platform and Innovation
IMC leverages a data-driven approach and a globally sourced product supply chain to provide premium cannabis products. The company's fully licensed EU-GMP packing facility and GDP logistics center in Germany enable efficient distribution and fulfillment services within the German market. IMC's commitment to compliance with strict regulatory environments ensures the quality and safety of its products.
Leadership Team
- Oren Shuster, Chief Executive Officer and Chairman of the Board
- Over 15 years of experience in the medical cannabis industry
- Co-founder of IMC and instrumental in its growth and expansion
- Moti Marcus, Director
- Extensive experience in finance and business development
- Served in various leadership roles in the financial sector
- Einat Zakariya, Director
- Background in law and corporate governance
- Experience in advising companies on regulatory compliance
- Brian Schinderle, Director
- Over 20 years of experience in investment management
- Expertise in capital markets and corporate finance
- Shmulik Arbel, Director
- Background in operations and supply chain management
- Experience in leading large-scale projects in various industries
Leadership Changes
In June 2024, Oren Shuster assumed the role of Chairman of the Board, succeeding Marc Lustig, who stepped down from the position. Mr. Lustig expressed confidence in Mr. Shuster's ability to lead the company, stating that the Chairman role would be in better hands with Oren, who can fully dedicate his focus to it.
Competitor Profile
Market Insights and Dynamics
The global medical cannabis market is experiencing significant growth, driven by increasing legalization and acceptance of cannabis for medical use. Germany's partial legalization of cannabis in April 2024 has opened new opportunities, with the market projected to reach a potential run rate of approximately $2 billion by the end of 2025, assuming a 1% penetration and an average spend of $200 per month.
Competitor Analysis
IMC faces competition from other international cannabis companies operating in Israel and Germany. Key competitors include:
- Tilray Brands, Inc.: A global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America.
- Aurora Cannabis Inc.: A Canadian company with a significant presence in the European medical cannabis market, including Germany.
- Canopy Growth Corporation: A diversified cannabis and cannabinoid-based consumer product company with operations in various international markets.
These competitors focus on expanding their product offerings and market presence in the rapidly growing medical cannabis industry.
Strategic Collaborations and Partnerships
IMC has established strategic collaborations to strengthen its market position and expand capabilities. In June 2024, the company entered into a supply agreement with EU-GMP certified GlassHouse Botanics Inc., headquartered in Whitewater, Ontario. This partnership aims to bolster IMC's supply chain with exclusive products, supporting accelerated growth in the German market following the partial legalization of cannabis.
Operational Insights
IMC's strategic focus on Israel and Germany positions the company to capitalize on the growing medical cannabis markets in these regions. The company's data-driven approach, compliance with strict regulatory environments, and strategic partnerships provide distinct competitive advantages. IMC's exit from the Canadian market allows for a concentrated effort on achieving sustainable and profitable growth in its highest-value markets.
Strategic Opportunities and Future Directions
IMC's strategic roadmap includes:
- Expansion in Germany: Leveraging the partial legalization of cannabis to increase market share and revenue.
- Product Diversification: Developing new cannabis products to meet diverse patient needs.
- Technological Advancements: Investing in technology to enhance product quality and operational efficiency.
- Regulatory Compliance: Ensuring adherence to evolving regulations to maintain market access and reputation.
By focusing on these areas, IMC aims to strengthen its position as a leading provider of premium medical cannabis products in Israel and Germany.
Contact Information
For more information, visit IM Cannabis Corp.'s official website.
Follow IMC on social media:
- Twitter:
- LinkedIn:
- Facebook:
- Instagram:
